Clin2
NCT06738901Possibly a fitNot yet recruiting

New factor VIII treatment for severe hemophilia A

Hemophilia A, Severe

Part of Blood & lymphatic, Genetic & congenital clinical trials.

This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
55 people
Ages
12 years to 65 years
Study type
Interventional

Who can take part

  • You are male, aged 12 to 65.
  • You have severe hemophilia A (factor VIII level below 1%).
  • You have had at least 150 past treatments with factor VIII products.
  • You do not have factor VIII inhibitors now or in the past.
  • You agree to use birth control if you could father a child.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07684898Recruiting· Phase 3
Long-acting factor VIII for severe hemophilia A

This trial tests a new long-acting factor VIII treatment (FRSW107) for people with severe hemophilia A. It aims to prevent bleeding episodes with fewer injections, and you must have already used factor VIII treatments many times before.

Tianjin, Tianjin Municipality
NCT07663903Recruiting· Phase 3
New longer-lasting factor VIII for severe hemophilia A (on-demand use)

This trial tests a new longer-lasting factor VIII medicine (FRSW107) for on-demand treatment of bleeding episodes. It is for males with severe hemophilia A who have been previously treated at least 150 times.

Tianjin, Tianjin Municipality
NCT06136507Not yet recruiting· Phase 3
Testing a new factor VIII drug for severe hemophilia A in children

This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.

Chongqing
NCT07226206Recruiting· Phase 1/Phase 2
Gene therapy for adults with severe hemophilia A

This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.

Orange, California
NCT06142552Recruiting· Phase 3
Study of a longer-lasting hemophilia A treatment for men

This trial tests a new form of factor VIII that lasts longer in the body, so you may need fewer infusions. It is for men with severe hemophilia A who have already used factor VIII products for at least 150 days.

Beijing
NCT07437404Recruiting· Phase 3
Testing SCT800 for previously untreated severe hemophilia A

This study tests a new medicine called SCT800 for boys with severe hemophilia A who have never been treated with factor VIII before. The goal is to see if it works safely to prevent bleeding.

Beijing, Beijing Municipality

Hear when a new Hemophilia A, Severe trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.